R&D Insights: How AstraZeneca PLC and Ultragenyx Pharmaceutical Inc. Allocate Funds

AstraZeneca vs. Ultragenyx: R&D Spending Showdown

__timestampAstraZeneca PLCUltragenyx Pharmaceutical Inc.
Wednesday, January 1, 2014557900000045967000
Thursday, January 1, 20155997000000114737000
Friday, January 1, 20165890000000183204000
Sunday, January 1, 20175757000000231644000
Monday, January 1, 20185932000000293998000
Tuesday, January 1, 20195958000000357355000
Wednesday, January 1, 20205991000000412084000
Friday, January 1, 20219736000000497153000
Saturday, January 1, 20229762000000705789000
Sunday, January 1, 202310935000000648449000
Monday, January 1, 202413583000000
Loading chart...

Igniting the spark of knowledge

R&D Investment Trends: AstraZeneca vs. Ultragenyx

In the ever-evolving pharmaceutical landscape, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, AstraZeneca PLC and Ultragenyx Pharmaceutical Inc. have demonstrated contrasting approaches to R&D investment.

From 2014 to 2023, AstraZeneca's R&D expenses surged by nearly 96%, peaking in 2023 with a remarkable $10.9 billion investment. This reflects AstraZeneca's strategic focus on expanding its drug pipeline and enhancing its competitive edge. In contrast, Ultragenyx, a smaller player, increased its R&D spending by over 1,300% during the same period, reaching $648 million in 2023. This underscores Ultragenyx's aggressive push to innovate in niche markets.

These trends highlight the diverse strategies employed by pharmaceutical giants and emerging companies alike, as they navigate the complex terrain of drug development and market competition.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025